Alterity Therapeutics Ltd (ASX:ATH) Share Price

Company Profile

Business description
Alterity Therapeutics Ltd is a clinical-stage biotechnology company focused on neurodegenerative diseases and the creation of a chemical library of proprietary molecules. Its research and clinical development efforts are focused on Parkinson's disease and related disorders, where it is identifying and developing novel compounds that address the underlying pathology of these disorders by binding and redistributing excess labile iron, reducing alpha-synuclein aggregation, and rescuing neurons in the brain. Its pipeline programs are ATH434-201, ATH434-202, bioMUSE, ATH434, and Drug Discovery. The Group operated in one segment: research and development into Parkinsonian and other neurodegenerative disorders.
Contact
500 Collins Street
Level 15
MelbourneVIC3000
AUS
T: +61 393494906
E: [email protected]
https://www.alteritytherapeutics.com
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
30 June 2027
Employees
11

Recommended

Growth projects could unlock significant value.

Mark Taylor | 13 October 2026

CXMT’s claimed tech breakthrough and an AI industry leader’s comments are weighing on stocks across the sector.

Karen Gilchrist | 13 October 2026

Stronger copper, aluminum and zinc prices offset by iron ore.

Jon Mills, CFA | 12 October 2026

Index	Last price	Change	% Change
All Ordinaries	8,869.00	52.50	-0.59%
CAC 40	7,873.11	45.48	0.58%
DAX 40	25,298.61	38.71	0.15%
Dow JONES (US)	51,446.98	223.12	-0.43%
FTSE 100	10,724.86	74.53	0.70%
HKSE	24,314.17	31.05	-0.13%
NASDAQ	26,634.78	569.61	-2.09%
Nikkei 225	67,744.29	33.23	-0.05%
NZX 50 Index	13,760.39	10.79	0.08%
S&P 500	7,701.83	103.62	-1.33%
S&P/ASX 200	8,727.90	56.00	-0.64%
SSE Composite Index	3,767.23	33.64	-0.88%